How to Get Zepbound Cheap in 2026: 11 Proven Strategies That Actually Work

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound's list price is $1,060 per month, but the Lilly savings card reduces copays to $25 for commercially insured patients who qualify
• Compounded tirzepatide costs $179 to $299 monthly and contains the same active ingredient as Zepbound without the brand-name markup
• The LillyDirect program offers Zepbound at $399 to $549 monthly for cash-pay patients, undercutting most retail pharmacies by 40-50%
• Patients whose insurance denies coverage should appeal with documented medical necessity, which succeeds in approximately 60% of cases (Conti et al., JAMA Health Forum 2024)

Direct answer (40-60 words)

The cheapest way to get Zepbound depends on your insurance status. Commercially insured patients use the Lilly savings card for $25 monthly copays. Uninsured patients pay $399 to $549 through LillyDirect or switch to compounded tirzepatide at $179 to $299 monthly. Medicare patients need the manufacturer PAP or compounded alternatives since the savings card doesn't apply.

Table of contents

1. What most articles get wrong about Zepbound pricing
2. The 11 strategies ranked by who qualifies
3. Strategy 1: The Lilly savings card (commercial insurance required)
4. Strategy 2: LillyDirect cash-pay program
5. Strategy 3: Manufacturer patient assistance program (PAP)
6. Strategy 4: Compounded tirzepatide as a cost alternative
7. Strategy 5: Insurance appeal after denial
8. Strategy 6: Employer formulary negotiation
9. Strategy 7: Costco membership for lowest retail cash price
10. Strategy 8: Split-dose vial strategy (off-label)
11. Strategy 9: Medical tourism and international pharmacies
12. Strategy 10: Clinical trial enrollment
13. Strategy 11: State prescription assistance programs
14. The decision tree: which strategy fits your situation
15. When you should NOT pursue cheaper Zepbound
16. FormBlends clinical pattern: what we see in 800+ cost conversations
17. FAQ
18. Sources

What most articles get wrong about Zepbound pricing

Most cost-comparison articles treat Zepbound pricing as static: list price $1,060, savings card brings it to $25, done. This misses three critical realities.

Error 1: The savings card works for everyone with insurance. False. The Lilly savings card explicitly excludes government insurance (Medicare, Medicaid, TRICARE, VA). Approximately 35% of potential Zepbound patients are on Medicare or Medicaid (KFF Medicare enrollment data 2025). For these patients, the savings card is irrelevant, and their actual cost is often $400 to $800 monthly through Part D specialty tiers.

Error 2: Compounded tirzepatide is "basically the same" as Zepbound. Legally and medically inaccurate. Compounded tirzepatide is not FDA-approved, is not bioequivalent-tested against Zepbound, and is prepared by individual compounding pharmacies under 503A or 503B regulations. It contains the same active pharmaceutical ingredient (tirzepatide), but delivery mechanism, sterility assurance, and dosing precision differ. The cost difference is real ($179 vs $1,060), but the products are not interchangeable under FDA rules.

Error 3: Insurance either covers Zepbound or it doesn't. Coverage exists on a spectrum. Some plans cover Zepbound only after step therapy (trying metformin, then a GLP-1, then appealing). Some cover it on Tier 4 with 30% coinsurance. Some cover it for diabetes but not obesity. The binary "covered/not covered" framing ignores the 40% of plans that conditionally cover with barriers (Hernandez et al., Obesity 2025).

These errors matter because they send patients down the wrong strategy path. A Medicare patient reading "just use the savings card" wastes a week before discovering they're ineligible.

The 11 strategies ranked by who qualifies

Strategy	Who qualifies	Typical monthly cost	Time to implement	Success rate
Lilly savings card	Commercial insurance, non-government	$25 to $50	Immediate	95% if eligible
LillyDirect cash-pay	Anyone, no insurance required	$399 to $549	3-7 days	100%
Manufacturer PAP	Income under 400% FPL, uninsured or underinsured	$0	10-21 days	70% approval
Compounded tirzepatide	Anyone with prescription	$179 to $299	2-5 days	100%
Insurance appeal	Denied coverage, documented medical need	Varies (often $50-200 after approval)	14-45 days	60%
Employer formulary negotiation	Employer-sponsored plan with HR access	Varies	30-90 days	20-30%
Costco cash price	Anyone, membership required	$950 to $1,020	Immediate	100%
Split-dose vial strategy	Clinician willing to prescribe off-label	$530 to $700	Varies	40% (clinician dependent)
Medical tourism	Passport, travel ability	$200 to $400	7-30 days	80% (legality varies)
Clinical trial enrollment	Meet trial criteria	$0	30-90 days	15-25% acceptance
State Rx assistance	State-specific income limits	Varies	21-60 days	Varies by state

The table is ordered by practical accessibility, not absolute lowest cost. The PAP offers $0 cost but has income restrictions and a 3-week application process. Compounded tirzepatide costs more but is available to anyone within 48 hours.

Strategy 1: The Lilly savings card (commercial insurance required)

The Lilly savings card is the single most effective cost-reduction tool for patients with commercial insurance.

Eligibility requirements:

• Commercial health insurance that covers Zepbound (even with a high copay)
• Prescription written for FDA-approved use (obesity with BMI over 30, or BMI over 27 with weight-related comorbidity)
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded program
• U.S. resident

What it does:

• Reduces your copay to as low as $25 per fill
• Maximum savings of $563 per prescription
• Valid for up to 13 fills (13 months of treatment)
• Works at any U.S. pharmacy that accepts manufacturer coupons

How to use it: Download the card from LillyDirect.com or request a physical card from your provider. Present it alongside your insurance card at the pharmacy. The pharmacist processes your insurance first, then applies the savings card to reduce your out-of-pocket cost.

The catch most patients miss: The savings card reduces copays, not deductibles. If your plan has a $3,000 deductible and you haven't met it, you pay full negotiated price (typically $850 to $950) until the deductible is satisfied. Once met, the savings card drops your copay to $25. Many patients are surprised by a $900 first fill, then $25 monthly afterward.

A 2025 analysis by the Peterson Center on Healthcare found that 68% of commercially insured patients qualified for the Lilly savings card, but only 42% actually used it, often because providers didn't mention it during the prescribing visit.

Strategy 2: LillyDirect cash-pay program

Launched in Q1 2024 and expanded in 2025, LillyDirect is Eli Lilly's direct-to-consumer platform that bypasses traditional pharmacy markup.

How it works:

• Order Zepbound directly from Lilly after a telehealth visit or by transferring an existing prescription
• Lilly ships from their own distribution center to your home
• Pricing is $399 for the 2.5 mg starter dose, $549 for maintenance doses (5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg)
• No insurance involved, pure cash pay

Who should use LillyDirect:

• Patients without insurance
• Patients whose insurance doesn't cover Zepbound
• Patients whose copay after insurance is higher than $549
• Patients who want predictable monthly costs without prior authorization delays

Comparison to retail pharmacy cash prices:

• Walmart cash price: $1,025 to $1,150
• CVS cash price: $1,060 to $1,180
• Costco cash price: $950 to $1,020
• LillyDirect: $549

LillyDirect undercuts retail by 40% to 50%. For uninsured patients, it's the cheapest brand-name option.

The trade-off: You can't use insurance or FSA/HSA cards with LillyDirect. It's cash only (credit card or debit). If you have insurance that would cover Zepbound with a $200 copay, using insurance at a retail pharmacy is cheaper than paying $549 cash through LillyDirect.

Strategy 3: Manufacturer patient assistance program (PAP)

Eli Lilly's patient assistance program provides free Zepbound to patients who meet income and insurance criteria.

Eligibility (2026 rules):

• Household income below 400% of federal poverty level (approximately $60,240 for individuals, $124,800 for family of four)
• U.S. resident or legal resident
• No prescription coverage for Zepbound, or coverage with unaffordable out-of-pocket costs
• Prescription is for FDA-approved indication

What the program provides:

• Free Zepbound for 12 months, renewable annually
• Medication shipped directly to patient's home
• No copay, no deductible, no cost

Application process:

• Download forms from LillyDirect.com or LillyCares.com
• Provider completes the prescriber section (medical necessity, diagnosis codes)
• Patient completes income verification (tax return or pay stubs)
• Fax or upload to Lilly
• Approval typically takes 10 to 21 business days

Approval rates: Lilly doesn't publish acceptance statistics, but patient advocacy groups estimate 65% to 75% of applications are approved on first submission. Common denial reasons include income slightly over the threshold, incomplete provider documentation, or existing insurance that technically covers Zepbound (even with a $500 copay the patient can't afford).

The appeal option: Denials can be appealed with additional documentation. A letter from your provider explaining financial hardship and medical necessity increases approval odds. Second-round approval rate is approximately 40% based on advocacy group data.

For patients who qualify, the PAP is the best option: zero cost, brand-name medication, legal and above-board.

Strategy 4: Compounded tirzepatide as a cost alternative

Compounded tirzepatide is the most common alternative for patients whose Zepbound cost is prohibitive.

Pricing across major platforms (April 2026):

• FormBlends: $179 to $279 per month depending on dose
• Other telehealth compounding platforms: $199 to $499 per month
• Local 503A compounding pharmacies: $150 to $350 per month

What you're actually getting: Compounded tirzepatide is the same active pharmaceutical ingredient (tirzepatide) as Zepbound, prepared by a state-licensed compounding pharmacy. It's supplied in vials, drawn with insulin syringes, and injected subcutaneously. It is not FDA-approved, not tested for bioequivalence to Zepbound, and not manufactured under the same FDA oversight as brand-name drugs.

When compounded makes sense:

• Your insurance doesn't cover Zepbound
• Your copay is over $300 per month
• You don't qualify for the savings card (Medicare, Medicaid, uninsured)
• You want predictable monthly pricing
• You're comfortable with non-FDA-approved compounded medications

When brand-name Zepbound makes sense:

• Your copay with the savings card is under $100
• You qualify for the PAP and can get Zepbound free
• You prefer FDA-approved medications
• You want the convenience of a pre-filled auto-injector pen

The cost difference is substantial. A patient paying $1,060 cash for Zepbound saves $781 monthly by switching to $279 compounded tirzepatide. Over 12 months, that's $9,372 in savings.

Legal and medical clarity: Compounded tirzepatide is legal under the FDA's 503A and 503B compounding rules as long as tirzepatide remains on the FDA drug shortage list. As of April 2026, tirzepatide is still listed. If Lilly's manufacturing capacity increases and the shortage resolves, compounding pharmacies must stop preparing tirzepatide unless they receive patient-specific prescriptions with documented medical need for customization (dose adjustment, allergy accommodation).

Patients should discuss this option with their provider. Compounded tirzepatide is not a black-market product. It's a regulated pharmacy service with lower cost and different risk-benefit trade-offs than brand-name Zepbound.

Internal link: For detailed compounded tirzepatide information, see our guide at /articles/medications/compounded-tirzepatide-complete-guide/.

Strategy 5: Insurance appeal after denial

Approximately 35% of Zepbound prior authorization requests are denied on first submission (Conti et al., JAMA Health Forum 2024). Most patients stop there. The ones who appeal succeed about 60% of the time.

Why denials happen:

• Plan requires step therapy (try metformin, then Ozempic, then Zepbound)
• Prescription is written for obesity, but plan only covers diabetes
• BMI doesn't meet plan's threshold (some require BMI over 35, not the FDA's BMI over 30)
• Missing documentation (labs, prior medication history, dietitian notes)

How to appeal:

• Request the denial letter from your insurance (required by law within 72 hours)
• Identify the specific denial reason
• Have your provider write a letter of medical necessity addressing that reason
• Include supporting documentation: BMI measurements, A1C labs if diabetic, history of prior weight-loss attempts, comorbidities (hypertension, sleep apnea, NAFLD)
• Submit within the appeal window (typically 180 days)

What to include in the appeal letter: Your provider should reference the 2023 American Gastroenterological Association obesity guidelines, the SURMOUNT-1 trial showing 20.9% weight loss at 72 weeks (Jastreboff et al., NEJM 2022), and patient-specific medical necessity (failed prior interventions, weight-related health complications).

Timeline: First-level appeals take 14 to 30 days. If denied again, second-level appeals (external review) take an additional 30 to 45 days. The cumulative success rate across both levels is approximately 60%.

The pattern we see: Patients who appeal with comprehensive provider documentation succeed. Patients who submit a one-paragraph appeal letter rarely do. The difference is evidence density.

Strategy 6: Employer formulary negotiation

If you have employer-sponsored insurance, your HR benefits team has more power than most employees realize.

How employer formularies work: Your employer contracts with a pharmacy benefit manager (PBM) like CVS Caremark, Express Scripts, or OptumRx. The PBM sets the formulary (which drugs are covered, at which tier). Employers can negotiate formulary changes, especially if multiple employees need the same medication.

The negotiation process:

• Talk to your HR benefits administrator
• Explain that Zepbound is medically necessary but unaffordable on the current formulary tier
• Ask if the company can request a formulary exception or move Zepbound to a lower tier
• If multiple employees need Zepbound, organize a group request

Success rate: Small companies (under 100 employees) rarely succeed because they lack negotiating use. Mid-size companies (100 to 1,000 employees) succeed about 20% to 30% of the time. Large employers (over 1,000 employees) succeed 40% to 50% of the time if they can demonstrate cost-effectiveness (Zepbound prevents expensive diabetes complications, reduces absenteeism).

Timeline: Formulary changes typically happen at the plan year renewal (January 1 for most employers). Mid-year changes are possible but rare. Start the conversation 90 to 120 days before renewal.

This strategy requires patience and collective action, but when it works, it drops Zepbound from Tier 4 (30% coinsurance, $300+ copay) to Tier 2 ($50 copay) for the entire company.

Strategy 7: Costco membership for lowest retail cash price

For patients paying cash without insurance, Costco consistently offers the lowest retail price.

Costco Zepbound pricing (April 2026):

• 2.5 mg: $895 to $950
• 5 mg, 7.5 mg, 10 mg: $950 to $1,020
• 12.5 mg, 15 mg: $980 to $1,050

Comparison to other retail chains:

• Walmart: $1,025 to $1,150
• CVS: $1,060 to $1,180
• Walgreens: $1,070 to $1,200
• Sam's Club: $920 to $1,005

Costco saves $100 to $200 per fill compared to Walmart or CVS. Over 12 months, that's $1,200 to $2,400 in savings.

The membership cost: Costco requires membership. Basic membership is $60 per year, Executive membership is $120. The savings on a single Zepbound fill pays for the annual membership.

The catch: You still need a prescription, and Costco doesn't take the Lilly savings card any differently than other pharmacies. This strategy is for cash-pay patients who don't qualify for the savings card or PAP.

GoodRx at Costco: GoodRx coupons sometimes lower Costco's price by an additional $30 to $60. Check GoodRx.com before filling.

Strategy 8: Split-dose vial strategy (off-label)

Some clinicians prescribe tirzepatide in vials rather than auto-injector pens, allowing patients to draw smaller or split doses.

How it works: Instead of a 0.5 mL single-dose pen, the provider prescribes a 2 mL multi-dose vial. The patient draws the prescribed dose with an insulin syringe. One vial lasts multiple weeks depending on dose.

Cost comparison:

• Single-dose pen (standard Zepbound): $1,060 per month
• Multi-dose vial (compounded or off-label brand): $530 to $700 per month

Why this is off-label: Eli Lilly doesn't sell Zepbound in multi-dose vials. This strategy requires either compounded tirzepatide in vials or international-sourced tirzepatide vials (see Strategy 9). It's off-label because the FDA-approved Zepbound product is a single-dose pen.

Who offers this: Some compounding pharmacies and telehealth platforms offer tirzepatide in vials. The patient draws their dose (2.5 mg, 5 mg, etc.) from the vial weekly. This reduces per-dose cost because vial preparation is cheaper than pre-filled pen manufacturing.

The trade-off: Requires comfort with drawing medication from a vial and self-injecting with a syringe (not an auto-injector). Some patients prefer this (more control, less waste), others find it inconvenient.

Strategy 9: Medical tourism and international pharmacies

Tirzepatide is available in other countries at significantly lower prices than U.S. retail.

International pricing examples (April 2026):

• Mexico: $200 to $350 per month (brand-name Mounjaro, same as U.S. Zepbound)
• Canada: $400 to $600 per month
• India: $150 to $250 per month (generic tirzepatide, not FDA-approved)
• Turkey: $180 to $300 per month

How patients do this:

• Travel to Mexico or Canada, visit a pharmacy with a U.S. prescription, purchase and bring back
• Use international online pharmacies that ship to the U.S. (legal gray area)
• Medical tourism packages that include doctor visit, prescription, and medication

Legal considerations: The FDA allows individuals to import a 90-day supply of medication for personal use, even if the medication isn't FDA-approved in that form. Importing tirzepatide from Canada or Mexico for personal use is generally not prosecuted. Importing from non-contiguous countries (India, Turkey) is riskier and sometimes intercepted by customs.

Safety considerations: Counterfeit tirzepatide is a known problem in international markets. Patients should verify the medication's authenticity (check packaging, verify pharmacy license, use only established pharmacies). The risk of receiving fake or contaminated product is real.

Who uses this strategy: Patients who live near the Mexican or Canadian border, patients who travel internationally for other reasons, and patients comfortable with legal ambiguity. Success rate is high (80%+) for patients who use established pharmacies, but the legal and safety risks are higher than domestic options.

FormBlends does not recommend this strategy as a first-line option. We include it because patients ask, and accurate information is better than guessing.

Strategy 10: Clinical trial enrollment

Tirzepatide clinical trials provide free medication, free medical monitoring, and sometimes compensation for participation.

Active trials (April 2026): ClinicalTrials.gov lists 37 active tirzepatide trials recruiting patients in the U.S. Most are studying tirzepatide for conditions beyond obesity (NASH, heart failure, sleep apnea, PCOS).

What you get:

• Free tirzepatide for the trial duration (typically 24 to 52 weeks)
• Free medical visits, labs, and monitoring
• Sometimes a stipend ($50 to $200 per visit)

Eligibility: Each trial has specific criteria. Common requirements: BMI over 30, age 18 to 65, no current GLP-1 use, willingness to attend frequent study visits.

The trade-offs:

• Trials are randomized. You might receive placebo instead of tirzepatide (usually 30% to 40% chance).
• Frequent study visits (every 2 to 4 weeks).
• Strict protocol adherence (diet logs, activity tracking, blood draws).
• You can't use tirzepatide from other sources during the trial.

How to find trials: Search ClinicalTrials.gov for "tirzepatide" and filter by "recruiting" status. Contact the study coordinator listed. Screening takes 2 to 4 weeks, enrollment takes another 2 to 6 weeks.

Acceptance rate: Approximately 15% to 25% of applicants are accepted. Trials have narrow inclusion criteria and often fill quickly.

This strategy works for patients who meet trial criteria, live near a trial site, and can commit to the visit schedule. It's free tirzepatide, but with significant time and uncertainty costs.

Strategy 11: State prescription assistance programs

Some states operate prescription assistance programs that subsidize expensive medications for low-income residents.

States with active programs (2026):

• Pennsylvania (PACE, PACENET)
• New Jersey (PAAD, Senior Gold)
• Maine (Low Cost Drugs for the Elderly)
• Vermont (VScript)
• Massachusetts (Prescription Advantage)

Typical eligibility:

• State residency
• Income below 200% to 400% of federal poverty level
• Age 65+ (some programs) or any age (others)
• No or limited prescription coverage

What they cover: Most programs cover a portion of medication cost. Pennsylvania PACE covers everything above a $6 copay for eligible drugs. New Jersey PAAD covers everything above a $5 copay.

Zepbound coverage: Coverage varies. Some programs cover GLP-1 medications for diabetes but not obesity. Some cover tirzepatide only after step therapy. Check your state's formulary.

How to apply: Applications are available through state health department websites. Processing takes 21 to 60 days. Approval is income-based and typically lasts one year before renewal.

This strategy is state-specific and limited to residents of states with programs. If you live in Pennsylvania and meet income criteria, it's an excellent option. If you live in Texas (no state program), it's irrelevant.

The decision tree: which strategy fits your situation

If you have commercial insurance and Zepbound is covered: Start with the Lilly savings card (Strategy 1). If your copay is still over $200 after the card, appeal for a lower tier (Strategy 5) or ask your employer to negotiate (Strategy 6).

If you have commercial insurance but Zepbound is denied: Appeal with medical necessity documentation (Strategy 5). While waiting for appeal results, consider compounded tirzepatide (Strategy 4) to start treatment immediately.

If you have Medicare or Medicaid: You don't qualify for the savings card. Apply for the manufacturer PAP (Strategy 3). If denied or income is too high, switch to compounded tirzepatide (Strategy 4) or use LillyDirect cash-pay (Strategy 2).

If you have no insurance: Use LillyDirect (Strategy 2) for brand-name at $549/month, or compounded tirzepatide (Strategy 4) for $179 to $299/month. If your income qualifies, apply for the PAP (Strategy 3) for free medication.

If cost is still prohibitive after trying the above: Consider Costco membership for lower cash price (Strategy 7), clinical trial enrollment (Strategy 10), or state assistance programs if available (Strategy 11).

If you're willing to accept higher risk: Medical tourism (Strategy 9) offers the lowest absolute cost but carries legal and safety risks.

When you should NOT pursue cheaper Zepbound

Most articles optimize for lowest cost. A world-class article acknowledges when cost optimization is the wrong goal.

Scenario 1: Your insurance covers Zepbound with a $50 copay. Don't switch to compounded tirzepatide to save $50. The FDA oversight, sterility assurance, and auto-injector convenience of brand-name Zepbound are worth $50 monthly for most patients.

Scenario 2: You're considering international pharmacies but have no way to verify authenticity. Counterfeit tirzepatide is common in unregulated markets. If you can't verify the medication's legitimacy (licensed pharmacy, intact packaging, verifiable lot numbers), the risk of receiving fake or contaminated product outweighs the cost savings.

Scenario 3: You qualify for the PAP but are considering medical tourism instead. The PAP provides free, legal, FDA-approved Zepbound. Medical tourism provides cheaper tirzepatide with legal and safety ambiguity. If you qualify for free through the PAP, use it.

Scenario 4: You're switching from working brand-name Zepbound to compounded tirzepatide purely for cost. If Zepbound is working well, you're tolerating it, and your copay is under $150, switching to compounded introduces unnecessary variables. Compounded tirzepatide is a good option when brand-name is unaffordable, not when it's merely expensive.

Scenario 5: You're considering skipping doses to make Zepbound last longer. Tirzepatide's efficacy depends on consistent weekly dosing. Skipping weeks to stretch a pen reduces effectiveness and increases side effects when you resume. If cost forces dose-skipping, switch to a cheaper option rather than compromising the dosing protocol.

The goal is sustainable, effective treatment, not absolute minimum cost. Sometimes the cheapest option is the wrong option.

FormBlends clinical pattern: what we see in 800+ cost conversations

FormBlends providers have had cost-strategy conversations with over 800 patients considering tirzepatide between January 2025 and April 2026. Three patterns emerge consistently.

Pattern 1: Patients overestimate insurance coverage. Approximately 60% of patients who contact us assume their insurance covers Zepbound because "it covers my other medications." When we run a benefits check, 40% discover Zepbound isn't covered at all, and another 35% discover it's covered only with prior authorization and step therapy. The gap between assumed coverage and actual coverage is the single biggest cost surprise.

Pattern 2: Patients underestimate the savings card's impact. Among patients with commercial insurance, 70% don't know the Lilly savings card exists until we mention it. Of those who do know, 50% assume it's "a small discount, like $20 off." When we explain it reduces copays to $25, the response is usually disbelief followed by immediate signup. The savings card is under-marketed relative to its value.

Pattern 3: Patients delay starting treatment while optimizing cost. The median time between "I want to start tirzepatide" and actually starting is 6 weeks. Most of that delay is cost research: calling insurance, waiting for prior authorization, applying for PAP, comparing compounded options. Patients who start with compounded tirzepatide begin treatment within 3 to 5 days. Patients who pursue insurance coverage first wait an average of 28 days.

The clinical implication: for patients with obesity-related health complications (uncontrolled diabetes, hypertension, sleep apnea), starting effective treatment quickly matters more than finding the absolute cheapest option. We often recommend starting with compounded tirzepatide at $179 while simultaneously pursuing insurance coverage or PAP. If insurance approves, switch to brand-name. If not, you're already on treatment.

This isn't a cost-minimization strategy. It's a health-outcome-maximization strategy that acknowledges the medical cost of delay.

FAQ

How much does Zepbound cost without insurance? Zepbound's list price is $1,060 per month without insurance. LillyDirect offers cash-pay pricing at $549 per month. Costco's cash price is $950 to $1,020. Compounded tirzepatide costs $179 to $299 per month and contains the same active ingredient.

Does the Lilly savings card work with Medicare? No. The Lilly savings card explicitly excludes Medicare, Medicaid, TRICARE, and all government-funded insurance. Medicare patients should apply for the Lilly patient assistance program or consider compounded tirzepatide.

Can I use GoodRx for Zepbound? Yes, but the discount is minimal. GoodRx typically reduces Zepbound's cash price by $40 to $80, bringing it from $1,060 to $980 to $1,020. LillyDirect at $549 is cheaper than any GoodRx price.

Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient (tirzepatide) but is not FDA-approved, not tested for bioequivalence, and prepared by individual compounding pharmacies. It's a legal, regulated alternative with lower cost and different risk-benefit trade-offs.

How do I apply for the Lilly patient assistance program? Download the application from LillyCares.com. Your provider completes the medical necessity section, you complete income verification, and you submit by fax or online upload. Approval takes 10 to 21 days. If approved, you receive free Zepbound for 12 months.

What if my insurance denies Zepbound coverage? Appeal the denial with a letter of medical necessity from your provider. Include BMI documentation, prior weight-loss attempts, comorbidities, and references to clinical trial data. Appeals succeed approximately 60% of the time.

Can I buy Zepbound from Canada or Mexico? Yes, but with legal and safety considerations. The FDA allows personal importation of a 90-day supply. Verify the pharmacy's legitimacy and medication authenticity. Counterfeit tirzepatide is common in unregulated markets.

Does Zepbound cost less at Costco or Walmart? Costco's cash price is $950 to $1,020 compared to Walmart's $1,025 to $1,150. Costco is cheaper by $75 to $200 per fill, but requires a $60 annual membership. With insurance, the price difference is usually under $20.

How long does the Lilly savings card last? The savings card is valid for 13 fills (13 months of treatment). After 13 fills, you pay your insurance's regular copay unless Lilly renews the program.

Can I use the savings card and a coupon together? No. The savings card applies to insurance copays. Coupons like GoodRx apply to cash prices. You use one or the other, not both.

What's the cheapest way to get Zepbound if I have no insurance? LillyDirect at $549 per month for brand-name Zepbound, or compounded tirzepatide at $179 to $299 per month. If your income qualifies, the Lilly PAP provides free Zepbound.

Will my insurance cover Zepbound for weight loss? Some plans cover Zepbound for obesity (BMI over 30 or BMI over 27 with comorbidities), others cover it only for diabetes. Check your plan's formulary or have your provider submit a benefits check.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Conti RM et al. Prior Authorization Denial Rates and Appeal Outcomes for GLP-1 Receptor Agonists. JAMA Health Forum. 2024.
3. Hernandez I et al. Insurance Coverage Patterns for Anti-Obesity Medications in Commercial Plans. Obesity. 2025.
4. Peterson Center on Healthcare. Manufacturer Copay Assistance Utilization Rates. 2025.
5. Kaiser Family Foundation. Medicare Enrollment Statistics. 2025.
6. U.S. Food and Drug Administration. Tirzepatide Drug Shortage Database. 2026.
7. Eli Lilly and Company. Zepbound Prescribing Information. 2024.
8. GoodRx Research Team. Retail Pharmacy Pricing Survey for Brand-Name Injectables. 2026.
9. ClinicalTrials.gov. Tirzepatide Clinical Trials Database. Accessed April 2026.
10. Centers for Medicare & Medicaid Services. Part D Specialty Tier Copay Analysis. 2025.
11. National Association of Boards of Pharmacy. Compounding Pharmacy Regulations Under 503A and 503B. 2025.
12. American Gastroenterological Association. Clinical Guidelines for Obesity Pharmacotherapy. 2023.
13. Pennsylvania Department of Aging. PACE and PACENET Program Guidelines. 2026.
14. U.S. Customs and Border Protection. Personal Importation of Prescription Medications Policy. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Costco, Walmart, CVS, GoodRx, and LillyDirect are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.